DOCSLIB.ORG

LEGISLATIVE ASSEMBLY Question on Notice

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

LEGISLATIVE ASSEMBLY Question On Notice Thursday, 15 February 2018 2560. Ms M. M Quirk to the Minister for Police; I refer to the commencement of operation of the Road Traffic Amendment Act 2016 in March 2017 which introduced compulsory blood or urine samples to be taken from drivers involved in serious crashes, and I ask: (a) since March 2017 how many such samples have been taken; (b) for what specific substances are those blood or urine samples tested; (c) what are the results of those tests to date; and (d) what percentage of drivers have been found to have ingested more than one substance capable of impairing driving skills? Answer (a) The compulsory taking of blood from all drivers involved in serious crashes commenced on 10 March 2017. Between 10 March 2017 and 22 February 2018 (inclusive) a total of 398 blood test samples have been collected under the provision of the Road Traffic Amendment Act 2016. There have been no urine tests collected. (b) Please see attached table for a list of substances in blood sample that are identifiable in ChemCentre toxicology analysis (Paper Number). (c) Of the 398 blood samples collected, 48 are pending results of ChemCentre analysis. Of the 350 analysed, 259 samples had a specific substance(s) detected and 91 samples had no specific substance detected. d) Of the 259 samples with specific substance(s) detected, 92% were found to have multiple substances (more than one). Detectable Substances in Blood Samples capable of identification by the ChemCentre WA. ACETALDEHYDE AMITRIPTYLINE/NORTRIPTYLINE METABOLITES ACETAZOLAMIDE AMLODIPINE ACETONE AMOXAPINE ACETYLCODEINE AMPHETAMINE ACETYLENE AMPHETAMINE & METHYLAMPHETAMINE ACETYLSALICYLATE AMPHETAMINE, EPHEDRINE & CAFFEINE ACETYLSALICYLIC ACID AMPHETAMINES ACONITINE AMPHETAMINES BY IMMUNOASSAY ALCOHOL AMPICILLIN ALCOHOL (CALC FOR LAST DRINK) AMYL NITRITE ALPHA NORTESTOSTERONE AMYLOBARBITONE ALPHA-BOLDENONE ANDROST-4-ENE-3,17-DIONE ALPRAZOLAM ANDROSTERONE ALPRENOLOL ARIPIPRAZOLE AMANTADINE ASPIRIN AMIDOPYRINE ATENOLOL AMILORIDE ATRACURIUM ARTEFACT/METABOLITE AMINOCLONAZEPAM ATROPINE AMINO-FLUNITRAZEPAM AZACYCLONOL AMINOGLUTETHIMIDE AZAPERONE AMINONITRAZEPAM AZATADINE AMIODARONE B HYDROXY-STANOZOLOL AMIODARONE METABOLITES BACLOFEN AMISULPRIDE BARBITONE AMITRIPTYLINE BARBITURATE AMITRIPTYLINE AND NORTRIPTYLINE BARBITURATES AMITRIPTYLINE METABOLITES BENZALKONIUM CHLORIDE AMITRIPTYLINE/NORTRIPTYLINE BENZENE BENZENE, TOLUENE AND XYLENES BROMPHENIRAMINE METABOLITE BENZHEXOL BUCLIZINE BENZOCAINE BUPIVACAINE BENZODIAZEPINE BUPRENORPHINE BENZODIAZEPINE METABOLITE BUPRENORPHINE (FREE) BENZODIAZEPINES BUPRENORPHINE (TOTAL) BENZODIAZEPINES BY IMMUNOASSAY BUPRENORPHINE BY CEDIA BENZODIAZEPINES IN URINE BY TDX BUPRENORPHINE BY ELISA BENZOPHENONE BUPRENORPHINE BY IMMUNOASSAY BENZOQUINONE BUPROPION BENZOYL ECGONINE BUPROPION METABOLITE BENZTROPINE BUSPIRONE BENZTROPINE METABOLITE BUTANE BENZYDAMINE BUTOBARBITONE BENZYDIAMINE BUTYL NITRITE BENZYLPIPERAZINE (BZP) CAFFEINE BETA NORTESTOSTERONE CANNABINOIDS BETA-BOLDENONE CANNABINOIDS (THC) BETAMETHASONE CANNABINOIDS BY IMMUNOASSAY BIPERIDEN CANNABIS BIPERIDEN METABOLITE CAPSAICINS (PEPPER SPRAY COMPONENTS) BISACODYL CAPTOPRIL BISOPROLOL CARBAMAZEPINE BISPHENOL A CARBAMAZEPINE EPOXIDE BOLDENONE CARBAMAZEPINE METABOLITE BOLDENONE UNDECYLENATE CARBON MONOXIDE BROMADIOLONE CARBON TETRACHLORIDE BROMAZEPAM CARBOXYTETRAHYDROCANNABINOL BROMOCHLORODIFLUOROMETHANE CARBROMAL BROMPHENIRAMINE CARISOPRODOL CARVEDILOL CITALOPRAM CATHINE CITALOPRAM AND METABOLITE CATHINONE CITALOPRAM METABOLITE CELECOXIB CLENBUTEROL CEPHALEXIN CLINDAMYACIN CHLORAL HYDRATE CLOBAZAM CHLORAMPHENICOL CLOBAZAM METABOLITE CHLORBUTOL CLOFIBRATE & METABOLITES CHLORCYCLIZINE CLOMIPRAMINE CHLORDIAZEPOXIDE CLOMIPRAMINE METABOLITE CHLORHEXIDINE CLONAZEPAM CHLORINATED HYDROCARBONS CLONAZEPAM AND METABOLITE CHLORINE CLONAZEPAM METABOLITE CHLORMETHIAZOLE CLONIDINE CHLOROFORM CLORBENZOREX CHLOROPHENE CLOZAPINE CHLOROQUINE CLOZAPINE & DESMETHYLCLOZAPINE CHLOROQUINE METABOLITE CLOZAPINE AND METABOLITE CHLORPHENAMINE CLOZAPINE AND METABOLITES CHLORPHENIRAMINE CLOZAPINE METABOLITE CHLORPHENIRAMINE AND METABOLITE COCAETHYLENE CHLORPHENIRAMINE METABOLITE COCAINE CHLORPROMAZINE COCAINE & METABOLITES CHLORPROMAZINE METABOLITE COCAINE BY IMMUNOASSAY CHLORPROPAMIDE COCAINE HYDROCHLORIDE CHLORTHIAZIDE COCAINE METABOLITES CIMETIDINE CODEINE CINCHOCAINE CODEINE & PARACETAMOL CISAPRIDE CODEINE (FREE) CISATRACURIUM CODEINE (TOTAL) CODEINE AND METABOLITE DEBRISOQUINE CODEINE AND NORCODEINE DEFERIPRONE CODEINE METABOLITES DEHYDROEPIANDROSTERONE COLCHICINE DEHYDROTESTOSTERONE UNDECYLATE COMMON ACID/NEUTRAL/BASIC DRUGS DEMOXEPAM COMMON ACIDIC/NEUTRAL DRUGS DESACETYLDILTIAZEM COMMON AMPHETAMINES DESALKYL QUETIAPINE COMMON ANABOLIC STEROIDS DESALKYLFLURAZEPAM COMMON ANTIDEPRESSANTS DESALKYLQUETIAPINE COMMON BASIC DRUGS DESALKYLVERAPAMIL COMMON BRONCHODILATORS DESCARBOETHOXYLORATADINE COMMON DRUGS DESCLOMIPRAMINE COMMON DRUGS OF ABUSE DESETHYLAMIODARONE COMMON DRUGS/POISONS DESETHYLCHLOROQUINE COMMON HYPNOTIC DRUGS DESIPRAMINE COMMON ILLICIT DRUGS DESIPRAMINE METABOLITES COMMON SOLVENTS DESMETHYCLOZAPINE COMMON TRICYCLIC ANTIDEPRESSANTS DESMETHYLCHLORPROMAZINE COMMON VOLATILE HYDROCARBONS DESMETHYLCITALOPRAM CONICEINE DESMETHYLCLOBAZAM CONIINE DESMETHYLCLOMIPRAMINE COTININE DESMETHYLCLOZAPINE CREATININE DESMETHYLDIAZEPAM CYANIDE DESMETHYLDIAZEPAM/TEMAZEPAM CYCLIZINE DESMETHYLDILTIAZEM CYCLOBARBITONE DESMETHYLDOTHIEPIN CYCLOHEXANE DESMETHYLDOXEPIN CYPROHEPTADINE DESMETHYLDOXYLAMINE CYPROHEPTADINE METABOLITE DESMETHYLMIANSERIN DANTROLENE DESMETHYLMIRTAZAPINE DESMETHYLMIRTAZEPINE DICLOFENAC DESMETHYLOLANZAPINE DICLOFENAC METABOLITE DESMETHYLPROMETHAZINE DICLOXACILLIN DESMETHYLQUETIAPINE DICYCLOMINE DESMETHYLSERTRALINE DIETHYL ETHER DESMETHYLSILDENAFIL DIETHYLCARBAMAZINE DESMETHYLTRAMADOL DIETHYLPROPION DESMETHYLTRIFLUOPERAZINE DIFLUNISAL DESMETHYLTRIMIPRAMINE DIFLUNISAL METABOLITE DESMETHYLVENLAFAXINE DIGOXIN DESMETHYLVERAPAMIL DIGOXIN BY IMMUNOASSAY DEXAMETHASONE DIHYDROCODEINE DEXAMPHETAMINE DIHYDROCODEINE (FREE) DEXCHLORPHENIRAMINE DIHYDROCODEINE (TOTAL) DEXTROMETHORPHAN DIHYDROCODEINE METABOLITE DEXTROMETHORPHAN AND METABOLITE DIHYDROERGOTAMINE DEXTROMETHORPHAN AND METABOLITESDIHYDROMORPHINE DEXTROMETHORPHAN METABOLITE DILTIAZEM DEXTROMORAMIDE DILTIAZEM AND DEACETYLDILTIAZEM DIACETYLMORPHINE DILTIAZEM AND METABOLITE DIACETYLMORPHINE (HEROIN) AND DILTIAZEM AND METABOLITES METABOLITE DILTIAZEM METABOLITE DIAZEPAM DILTIAZEM METABOLITES DIAZEPAM & DESMETHYLDIAZEPAM DIMENHYDRINATE DIAZEPAM AND METABOLITES DIMETHYLAMPHETAMINE DIAZEPAM METABOLITES DIMETHYLSULPHIDE DIBENZEPIN DIMETHYLTRYPTAMINE DIBENZYLPIPERAZINE. DIPHENHYDRAMINE DICHLOROETHANE DIPHENHYDRAMINE AND METABOLITE DICHLOROMETHANE DIPHENHYDRAMINE HYDROCHLORIDE DIPHENHYDRAMINE METABOLITE EPHEDRINE/PSEUDOEPHEDRINE DIPHENHYDRAMINE/ORPHENADRINE EPHEDRINE/PSEUDOEPHEDRINE ARTEFACT DIPYRIDAMOLE EPHEDRINE/PSEUDOEPHEDRINE METABOLITE DISOPYRAMIDE EPITESTOSTERONE DISULFIRAM ERGOTAMINE DOBUTAMINE ERYTHRO/THREOHYDROBUPROPION DOTHIEPIN ERYTHROHYDROBUPROPION DOTHIEPIN AND METABOLITES ERYTHROMYCIN DOTHIEPIN METABOLITE ERYTHROPOIETIN DOTHIEPIN METABOLITES ETHANOL DOXAPRAM ETHANOL-2-(2-BUTOXY) DOXEPIN ETHCHLORVYNOL DOXEPIN & METABOLITES ETHER DOXEPIN AND DESMETHYLDOXEPIN ETHINYLOESTRADIOL DOXEPIN METABOLITE ETHOSUXIMIDE DOXEPIN METABOLITES ETHYL CHLORIDE DOXYCYCLINE ETHYL GLUCURONIDE DOXYLAMINE ETHYL SALICYLATE DOXYLAMINE AND METABOLITE ETHYLAMPHETAMINE DOXYLAMINE METABOLITE ETHYLBENZENE DROPERIDOL ETHYLENE GLYCOL DULOXETINE ETORPHINE ECONAZOLE FAMOTIDINE EFAVIRENZ FELODIPINE EMETINE FENFLURAMINE ENALAPRIL FENOPROFEN ENALAPRIL METABOLITE FENTANYL EPHEDRINE FENTANYL BY ELISA EPHEDRINE & CAFFEINE FLECAINIDE EPHEDRINE METABOLITE FLUANISONE FOSINOPRIL SODIUM FLUCLOXACILLIN FREE DIHYDROCODEINE FLUCONAZOLE FREE NALTREXOL FLUFENAMIC ACID FREE NALTREXONE FLUMAZENIL FREE OXYCODONE FLUNITRAZEPAM FRUSEMIDE FLUNITRAZEPAM & METABOLITES GABAPENTIN FLUNITRAZEPAM (ROHYPNOL) GAMMA BUTYROLACTONE FLUNITRAZEPAM METABOLITE GAMMA HYDROXYBUTYRIC ACID (GHB) FLUNITRAZEPAM METABOLITES GEMFIBROZIL FLUNIXIN GEMFIBROZIL METABOLITE FLUORIDE GLIBENCLAMIDE FLUOTHANE GLICLAMIDE FLUOXETINE GLICLAZIDE FLUOXETINE AND ARTEFACT GLICLAZIDE ARTEFACT FLUOXETINE AND METABOLITE GLICLAZIDE ARTIFACT FLUOXETINE ARTEFACT GLICLAZIDE METABOLITE FLUOXETINE METABOLITE GLIPAZIDE FLUOXETINE/ NORFLUOXETINE GLIPIZIDE FLUOXETINE/NORFLUOXETINE GLUTETHIMIDE FLUOXYMESTERONE GLYCERYL TRINITRATE FLUPENTHIXOL GLYCOPYRROLATE FLUPHENAZINE GUAIFENESIN FLURAZEPAM HALOPERIDOL FLURAZEPAM METABOLITE HALOPERIDOL AND METABOLITE FLUVOXAMINE HALOTHANE FLUVOXAMINE ARTEFACT HARMALINE FLUVOXAMINE METABOLITES HARMINE FORMALDEHYDE HELIUM FOSINOPRIL HEPTANE HEROIN HYDROXYPROGESTERONE HEXANOATE HEROIN HCL HYDROXYSTANOZOLOL HEROIN METABOLITE HYDROXY-TRIAZOLAM HEXAMINE HYDROXYZINE HEXANE HYOSCINE HEXOBARBITONE HYOSCINE (SCOPOLAMINE) METABOLITE HEXYLENE GLYCOL HYOSCINE HYDROBROMIDE HYDROCARBON SOLVENTS IBUPROFEN HYDROCARBONS IBUPROFEN AND METABOLITES HYDROCHLORTHIAZIDE IBUPROFEN METABOLITE HYDROCODEINE IBUPROFEN METABOLITES HYDROCODONE IMIPRAMINE HYDROCORTISONE IMIPRAMINE & METABOLITES HYDROGEN SULPHIDE IMIPRAMINE METABOLITE HYDROMORPHONE IMIPRAMINE METABOLITES HYDROMORPHONE (FREE) INDOMETHACIN HYDROMORPHONE (TOTAL) INDOMETHACIN METABOLITE HYDROQUINONE INSULIN HYDROXY-ALPRAZOLAM IRBERSARTAN METABOLITE HYDROXYANDROSTANEDINONE IRBESARTAN HYDROXYBUPROPION IRBESARTEN & METABOLITES HYDROXYCHLOROQUINE ISO-AMYL ACETATE HYDROXYCHLOROQUINE AND METABOLITEISOAMYL ALCOHOL HYDROXYCHLORPROMAZINE ISOAMYL NITRITE HYDROXYDESALKYLQUETIAPINE
Recommended publications
  • Colitis Caused by Non-Steroidal Anti-Inflammatory Drugs

    Colitis Caused by Non-Steroidal Anti-Inflammatory Drugs

    Postgrad Med J: first published as 10.1136/pgmj.62.730.773 on 1 August 1986. Downloaded from Postgraduate Medical Journal (1986) 62, 773-776 Colitis caused by non-steroidal anti-inflammatory drugs S. Ravi', A.C. Keat2 and E.C.B. Keat1 'Cuckfield Hospital, Cuckfield, West Sussex, and2Westminster Hospital, Horseferry Road, London SWIP2AP, UK. Summary: Four cases of acute proctocolitis associated with non-steroidal anti-inflammatory drug therapy are presented. The drugs implicated were flufenamic acid, mefenamic acid, naproxen and ibuprofen. After resolution of symptoms and signs of proctocolitis three of the four patients were subsequently rechallenged with the implicated drug: in each there was a rapid relapse. Introduction Ulcerative colitis is a disease of unknown aetiology Case reports with characteristic clinical features and a protracted course. A similar clinical picture, but running a shorter Case I and usually benign course, is occasionally seen follow- ing the administration of certain drugs. This was first A 77 year old woman was referred with intermittent noticed following the administration of antibiotics, bleeding per rectum for 6 months, associated for the often with pseudomembrane formation. Later, this last 2 months with bloody diarrhoea up to eight times was shown to be associated with infection by toxigenic daily. Previously, she had had troublesome symptoms Clostridium difficile. Until 1978, most cases were from osteoarthritis of her back and knees for which copyright. associated with treatment with clindamycin but since she had been prescribed flufenamic acid 200 mg thrice that time nearly all antibiotics have been implicated. daily. Her general health had remained good but she Other drugs capable of causing proctocolitis, though appeared pale and her haemoglobin was reduced to by different mechanisms, include phenindione (Keat & 8 g/dl.
  • Impact of CYP2C19 Genotype on Sertraline Exposure in 1200 Scandinavian Patients

    Impact of CYP2C19 Genotype on Sertraline Exposure in 1200 Scandinavian Patients

    www.nature.com/npp ARTICLE Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients Line S. Bråten 1,2, Tore Haslemo1,2, Marin M. Jukic3,4, Magnus Ingelman-Sundberg 3, Espen Molden1,5 and Marianne K. Kringen1,2 Sertraline is an (SSRI-)antidepressant metabolized by the polymorphic CYP2C19 enzyme. The aim of this study was to investigate the impact of CYP2C19 genotype on the serum concentrations of sertraline in a large patient population. Second, the proportions of patients in the various CYP2C19 genotype-defined subgroups obtaining serum concentrations outside the therapeutic range of sertraline were assessed. A total of 2190 sertraline serum concentration measurements from 1202 patients were included retrospectively from the drug monitoring database at Diakonhjemmet Hospital in Oslo. The patients were divided into CYP2C19 genotype-predicted phenotype subgroups, i.e. normal (NMs), ultra rapid (UMs), intermediate (IMs), and poor metabolisers (PMs). The differences in dose-harmonized serum concentrations of sertraline and N-desmethylsertraline-to-sertraline metabolic ratio were compared between the subgroups, with CYP2C19 NMs set as reference. The patient proportions outside the therapeutic concentration range were also compared between the subgroups with NMs defined as reference. Compared with the CYP2C19 NMs, the sertraline serum concentration was increased 1.38-fold (95% CI 1.26–1.50) and 2.68-fold (95% CI 2.16–3.31) in CYP2C19 IMs and PMs, respectively (p < 0.001), while only a marginally lower serum concentration (−10%) was observed in CYP2C19 UMs (p = 0.012). The odds ratio for having a sertraline concentration above the therapeutic reference range was 1.97 (95% CI 1.21–3.21, p = 0.064) and 8.69 (95% CI 3.88–19.19, p < 0.001) higher for IMs and PMs vs.
  • ZOLOFT® 50 Mg and 100 Mg Tablets

    ZOLOFT® 50 Mg and 100 Mg Tablets

    NEW ZEALAND DATA SHEET 1. PRODUCT NAME ZOLOFT® 50 mg and 100 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 50 mg tablet contains sertraline hydrochloride equivalent to 50 mg sertraline. Each 100 mg tablet contains sertraline hydrochloride equivalent to 100 mg sertraline. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM ZOLOFT 50 mg tablets: white film-coated tablets marked with the Pfizer logo on one side and “ZLT” scoreline “50” on the other. Approximate tooling dimensions are 1.03 cm x 0.42 cm x 0.36 cm. ZOLOFT 100 mg tablets: white film-coated tablets marked with the Pfizer logo on one side and “ZLT-100” or “ZLT 100” on the other. Approximate tooling dimensions are 1.31 cm x 0.52 cm x 0.44 cm. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Adults ZOLOFT is indicated for the treatment of symptoms of depression, including depression accompanied by symptoms of anxiety, in patients with or without a history of mania. Following satisfactory response, continuation with ZOLOFT therapy is effective in preventing relapse of the initial episode of depression or recurrence of further depressive episodes. ZOLOFT is indicated for the treatment of obsessive compulsive disorder (OCD). Following initial response, sertraline has been associated with sustained efficacy, safety and tolerability in up 2 years of treatment of OCD. ZOLOFT is indicated for the treatment of panic disorder, with or without agoraphobia. ZOLOFT is indicated for the treatment of post-traumatic stress disorder (PTSD). ZOLOFT is indicated for the treatment of social phobia (social anxiety disorder).
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0100249 A1 Sears Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2014/0100249 A1 Sears Et Al

    US 201401.00249A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0100249 A1 Sears et al. (43) Pub. Date: Apr. 10, 2014 (54) THERAPEUTIC TREATMENT A63/37 (2006.01) A613 L/45 (2006.01) (71) Applicants: Douglas Sears, Oak Park, CA (US); A613 L/4458 (2006.01) Michael Reilly, Oak Park, CA (US) (52) U.S. Cl. CPC ............... A61K 45/06 (2013.01); A61 K3I/451 (72) Inventors: Douglas Sears, Oak Park, CA (US); (2013.01): A613 L/4458 (2013.01); A61 K Michael Reilly, Oak Park, CA (US) 3 1/137 (2013.01); A61 K31/165 (2013.01) USPC .......................................................... S14/325 (21) Appl. No.: 14/046,528 (57) ABSTRACT (22) Filed: Oct. 4, 2013 This invention discloses a treatment for a patient receiving O O medication to treat an attention deficit disorder Such as Related U.S. Application Data ADHD wherein the treatment results in a loss of appetite and (60) Provisional application No. 61/744,948, filed on Oct. impairment of the patient's attentiveness. The treatment com 9, 2012, now abandoned. bines a treatment for an attention deficit disorder with an appetite stimulant, wherein the appetite stimulant increases Publication Classification the caloric intake of a patient, which can increase the patients attentiveness. The combination treatment can be given for an (51) Int. Cl. indefinite, including, without limitation, life-long, to allow a A6 IK 45/06 (2006.01) patient to maintain normal caloric intake during treatment for A6 IK3I/65 (2006.01) an attention deficit disorder. 8aasaias: Patent Application Publication Apr. 10, 2014 Sheet 1 of 22 US 2014/010O249 A1 Figure i: improvement in Atiention with increased Caiotic intake 8aakast Patent Application Publication Apr.
  • Investigating the Influence of Polymers on Supersaturated

    Investigating the Influence of Polymers on Supersaturated

    Page 1 of 45 Molecular Pharmaceutics 1 2 3 4 5 6 7 Investigating the Influence of Polymers on 8 9 10 11 12 Supersaturated Flufenamic Acid Cocrystal Solutions 13 14 15 16 1 1 2 2 1 17 Minshan Guo , Ke Wang , Noel Hamill , Keith Lorimer and Mingzhong Li * 18 19 20 1School of pharmacy, De Montfort University, Leicester, UK 21 22 23 2Almac Science, Seagoe Industrial Estate, Craigavon, UK 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 ACS Paragon Plus Environment 1 Molecular Pharmaceutics Page 2 of 45 1 2 3 4 5 6 7 Table of contents graphic 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 ACS Paragon Plus Environment 2 Page 3 of 45 Molecular Pharmaceutics 1 2 3 Abstract 4 5 6 7 The development of enabling formulations is a key stage when demonstrating the effectiveness 8 9 10 of pharmaceutical cocrystals to maximize the oral bioavailability for poorly water soluble drugs. 11 12 Inhibition of drug crystallization from a supersaturated cocrystal solution through a fundamental 13 14 understanding of the nucleation and crystal growth is important. In this study, the influence of 15 16 17 the three polymers of polyethylene glycol (PEG), polyvinylpyrrolidone (PVP) and a copolymer 18 19 of N-vinly-2-pyrrodidone (60%) and vinyl acetate (40%) (PVP-VA) on the flufenamic acid 20 21 22 (FFA) crystallization from three different supersaturated solutions of the pure FFA and two 23 24 cocrystals of FFA-NIC CO and FFA-TP CO has been investigated by measuring nucleation 25 26 induction times and desupersaturation rates in the presence and absence of seed crystals.
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And

    Upregulation of Peroxisome Proliferator-Activated Receptor-Α And

    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
  • Ranvet's Filybol

    Ranvet's Filybol

    Ranvet's Filybol Ranvet Chemwatch Hazard Alert Code: 2 Chemwatch: 4787-83 Issue Date: 08/02/2016 Version No: 5.1.1.1 Print Date: 10/28/2016 Safety Data Sheet according to WHS and ADG requirements S.GHS.AUS.EN SECTION 1 IDENTIFICATION OF THE SUBSTANCE / MIXTURE AND OF THE COMPANY / UNDERTAKING Product Identifier Product name Ranvet's Filybol Chemical Name peanut oil Synonyms Not Available Other means of Not Available identification Relevant identified uses of the substance or mixture and uses advised against Relevant identified Non-virilising anabolic combination for fillies, mares, colts and stallions. uses Details of the supplier of the safety data sheet Registered company Ranvet name Address 10-12 Green Street Banksmeadow NSW 2019 Australia Telephone +61 2 9666 1744 Fax +61 2 9666 1755 Website https://www.ranvet.com.au/other_msds.htm Email [email protected] Emergency telephone number Association / Not Available Organisation Emergency telephone +61 425 061 584 numbers Other emergency Not Available telephone numbers SECTION 2 HAZARDS IDENTIFICATION Classification of the substance or mixture Poisons Schedule S4 Carcinogenicity Category 2, Reproductive Toxicity Category 2, Acute Aquatic Hazard Category 2, Chronic Aquatic Hazard Classification [1] Category 2 1. Classified by Chemwatch; 2. Classification drawn from HSIS ; 3. Classification drawn from EC Directive 1272/2008 - Annex Legend: VI Label elements GHS label elements SIGNAL WORD WARNING Continued... Chemwatch: 4787-83 Page 2 of 10 Issue Date: 08/02/2016 Version No: 5.1.1.1 Ranvet's Filybol Print Date: 10/28/2016 Hazard statement(s) H351 Suspected of causing cancer. H361 Suspected of damaging fertility or the unborn child.
  • 2015-02 Toxicology Rapid Testing Panel

    2015-02 Toxicology Rapid Testing Panel

    SOUTH CAROLINA LAW ENFORCEMENT DIVISION NIKKI R. HALEY MARK A. KEEL Governor Chief FORENSIC SERVICES LABORATORY CUSTOMER NOTICE 2015-02 REGARDING TOXICOLOGY RAPID TESTING PANEL August 12, 2015 This notice is to inform the Coroners of South Carolina of a new testing panel available through the SLED Toxicology Department. On Monday, August 17th, the Toxicology Department will begin offering both a Rapid Testing Panel in addition to the already available Expanded Testing Panel. This Rapid Testing Panel is to be utilized in cases where the Expanded Testing Panel is not warranted, specifically where a cause of death has already been established. The Rapid Testing Panel will consist of volatiles analysis, to include, ethanol, acetone, isopropanol and methanol, drug screens, and drug confirmation/quantitation of positive screens. The cases assigned to the Rapid Testing Panel will have an expedited turnaround time. Targeted turn around times will be two weeks for negative cases and six weeks or less for positive cases. While every effort will be made to adhere to these time frames, additional time may be required on occasion due to the nature of postmortem samples. Submitters will be notified if there is a problem with a particular sample. Please see attachment regarding specifically which substances are covered by the Rapid Testing Panel and the Expanded Testing Panel. As always, a detailed case history and list of drugs suspected is appreciated. Rapid Panel and Expanded Panel will be choices available in iLAB. Please contact Lt. Dustin Smith (803-896-7385) with additional questions. ALI-359-T An Accredited Law Enforcement Agency P.O.
  • Properties and Units in Clinical Pharmacology and Toxicology

    Properties and Units in Clinical Pharmacology and Toxicology

    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
  • Programme & Abstracts

    Programme & Abstracts

    The 57th Annual Meeting of the International Association of Forensic Toxicologists. 2nd - 6th September 2019 BIRMINGHAM, UK The ICC Birmingham Broad Street, Birmingham B1 2EA Programme & Abstracts 1 Thank You to our Sponsors PlatinUm Gold Silver Bronze 2 3 Contents Welcome message 5 Committees 6 General information 7 iCC maps 8 exhibitors list 10 Exhibition Hall 11 Social Programme 14 opening Ceremony 15 Schedule 16 Oral Programme MONDAY 2 September 19 TUESDAY 3 September 21 THURSDAY 5 September 28 FRIDAY 6 September 35 vendor Seminars 42 Posters 46 oral abstracts 82 Poster abstracts 178 4 Welcome Message It is our great pleasure to welcome you to TIAFT Gala Dinner at the ICC on Friday evening. On the accompanying pages you will see a strong the UK for the 57th Annual Meeting of scientific agenda relevant to modern toxicology and we The International Association of Forensic thank all those who submitted an abstract and the Toxicologists Scientific Committees for making the scientific programme (TIAFT) between 2nd and 6th a success. Starting with a large Young Scientists September 2019. Symposium and Dr Yoo Memorial plenary lecture by Prof Tony Moffat on Monday, there are oral session topics in It has been decades since the Annual Meeting has taken Clinical & Post-Mortem Toxicology on Tuesday, place in the country where TIAFT was founded over 50 years Human Behaviour Toxicology & Drug-Facilitated Crime on ago. The meeting is supported by LTG (London Toxicology Thursday and Toxicology in Sport, New Innovations and Group) and the UKIAFT (UK & Ireland Association of Novel Research & Employment/Occupational Toxicology Forensic Toxicologists) and we thank all our exhibitors and on Friday.
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • Part I Biopharmaceuticals

    Part I Biopharmaceuticals

    1 Part I Biopharmaceuticals Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 3 1 Analogs and Antagonists of Male Sex Hormones Robert W. Brueggemeier The Ohio State University, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Columbus, Ohio 43210, USA 1Introduction6 2 Historical 6 3 Endogenous Male Sex Hormones 7 3.1 Occurrence and Physiological Roles 7 3.2 Biosynthesis 8 3.3 Absorption and Distribution 12 3.4 Metabolism 13 3.4.1 Reductive Metabolism 14 3.4.2 Oxidative Metabolism 17 3.5 Mechanism of Action 19 4 Synthetic Androgens 24 4.1 Current Drugs on the Market 24 4.2 Therapeutic Uses and Bioassays 25 4.3 Structure–Activity Relationships for Steroidal Androgens 26 4.3.1 Early Modifications 26 4.3.2 Methylated Derivatives 26 4.3.3 Ester Derivatives 27 4.3.4 Halo Derivatives 27 4.3.5 Other Androgen Derivatives 28 4.3.6 Summary of Structure–Activity Relationships of Steroidal Androgens 28 4.4 Nonsteroidal Androgens, Selective Androgen Receptor Modulators (SARMs) 30 4.5 Absorption, Distribution, and Metabolism 31 4.6 Toxicities 32 Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 4 Analogs and Antagonists of Male Sex Hormones 5 Anabolic Agents 32 5.1 Current Drugs on the Market 32 5.2 Therapeutic Uses and Bioassays